
|Videos|October 19, 2021
Patient Case #2 Continued: Novel Second-Generation Antipsychotics
A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial: The Power of Another COMP360 Dose
2
The Postmodern Worldview and Contemporary Psychiatry
3
New Phase 2 Clinical Trial Initiating in 2027: Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder
4
DT120 (Lysergide) ODT Receives Breakthrough Therapy Designation for Treatment of MDD
5










